Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Brian J, Skaggs"'
Autor:
Brian J. Skaggs, Jennifer Grossman, Lori Sahakian, Lucas Perry, John FitzGerald, Christina Charles‐Schoeman, Alan Gorn, Mihaela Taylor, John Moriarty, Nagesh Ragavendra, Michael Weisman, Daniel J. Wallace, Bevra H. Hahn, Maureen McMahon
Publikováno v:
ACR Open Rheumatology, Vol 3, Iss 4, Pp 209-220 (2021)
Objective The increase in cardiovascular events (CVEs) in systemic lupus erythematosus (SLE) is not fully explained by traditional risk factors. We previously identified four biomarkers (proinflammatory high‐density lipoprotein, leptin, soluble TNF
Externí odkaz:
https://doaj.org/article/02966150902547ddb3354a6c17ef0378
Autor:
Michael H. Weisman, Daniel J. Wallace, Lori Sahakian, Bevra H. Hahn, John FitzGerald, John M. Moriarty, Lucas Perry, Christina Charles-Schoeman, Mihaela Taylor, Maureen McMahon, Nagesh Ragavendra, Jennifer M. Grossman, Brian J. Skaggs, Alan Gorn
Publikováno v:
ACR Open Rheumatology
ACR Open Rheumatology, Vol 3, Iss 4, Pp 209-220 (2021)
ACR open rheumatology, vol 3, iss 4
ACR Open Rheumatology, Vol 3, Iss 4, Pp 209-220 (2021)
ACR open rheumatology, vol 3, iss 4
ObjectiveThe increase in cardiovascular events (CVEs) in systemic lupus erythematosus (SLE) is not fully explained by traditional risk factors. We previously identified four biomarkers (proinflammatory high-density lipoprotein, leptin, soluble TNF-li
Autor:
Brian J. Skaggs, Maureen McMahon
Cardiovascular disease is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Noncoronary cardiac involvement occurs in up to 40% of lupus patients. Increased atherosclerosis, myocardial infarction, and stroke are also sig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac1c9d75d2e8f858e4a704404feb22ea
https://doi.org/10.1016/b978-0-12-820583-9.00035-x
https://doi.org/10.1016/b978-0-12-820583-9.00035-x
Autor:
Maureen McMahon, Bevra H. Hahn, Jennifer M. Grossman, Brian J. Skaggs, Lori Sahakian, Weng Kee Wong, Weiling Chen
Publikováno v:
Lupus Science & Medicine
ObjectivePatients with SLE have an increased risk of atherosclerosis (ATH) that is not adequately explained by traditional risk factors. We previously described the Predictors of Risk for Elevated Flares, Damage Progression, and Increased Cardiovascu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff50178b4631f013a36ea051f86ae85b
https://escholarship.org/uc/item/9wz962b4
https://escholarship.org/uc/item/9wz962b4
Publikováno v:
Abstracts Accepted for Publication.
Background Fatigue is highly prevalent and has a negative impact on quality of life in patients with Systemic Lupus Erythematosus.1,2 The 9-item Fatigue Severity Scale (FSS) is one of the commonly used self-report questionnaires to measure fatigue in
Publikováno v:
Poster Session.
Background and aims Women with SLE have an increased risk of atherosclerosis that is not adequately explained by traditional risk factors. We previously discovered that a “high risk” score on a panel of biomarkers, PREDICTS, confers 28-fold incre
Publikováno v:
Poster Session.
Background and aims Women with SLE have increased atherosclerosis (ATH) that is not adequately explained by traditional risk factors. We previously discovered that a “high risk” score on a panel of biomarkers, PREDICTS , confers 28-fold increased
Autor:
Michael R. Burgess, Charles L. Sawyers, John Wongvipat, Minna D. Balbas, Rajmohan Murali, Astrid Weins, Peter Mundel, Brian J. Skaggs
Publikováno v:
Proceedings of the National Academy of Sciences. 111:14876-14881
MAGUK Inverted 2 (MAGI-2) is a PTEN-interacting scaffold protein implicated in cancer on the basis of rare, recurrent genomic translocations and deletions in various tumors. In the renal glomerulus, MAGI-2 is exclusively expressed in podocytes, speci
Publikováno v:
Arthritis & Rheumatology. 66:674-685
Objective Lupus nephritis depends on autoantibody deposition and activation of multiple immune cell types that promote kidney inflammation, including lymphocytes and monocyte/macrophages. Laquinimod, currently in clinical trials for multiple sclerosi
Autor:
John FitzGerald, Michael H. Weisman, Brian J. Skaggs, Weng Kee Wong, Bevra H. Hahn, Maureen McMahon, Nagesh Ragavendra, Jennifer M. Grossman, Elaine V. Lourenço, Mihaela Taylor, Karol E. Watson, Lori Sahakian, Alan Gorn, Daniel J. Wallace, Christina Charles-Schoeman, George Karpouzas
Publikováno v:
Arthritis & Rheumatology. 66:130-139
Objective An increased frequency of atherosclerosis (ATH) in systemic lupus erythematosus (SLE) is well-documented but not fully explained by the presence of traditional cardiac risk factors. Several nontraditional biomarkers, including proinflammato